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Monitoring of antigen-specific T-cell responses is valuable in numerous conditions that include infectious diseases, vaccinations,
and opportunistic infections associated with acquired or congenital immune defects. A variety of assays that make use of periph-
eral lymphocytes to test activationmarkers, T-cell receptor expression, or functional responses are currently available. The last
group of assays calls for large numbers of functional lymphocytes. The number of cells increases with the number of antigens to
be tested. Consequently, cells may be the limiting factor, particularly in lymphopenic subjects and in children, the groups that
more often require immunemonitoring. We have developed immunochemical assays that measure secreted cytokines in the
same wells in which peripheral bloodmononuclear cells (PBMC) are cultured. This procedure lent itself to miniaturization and
automation. Lymphoproliferation and the enzyme-linked immunosorbent spot (ELISPOT) assay have been adapted to a minia-
turized format. Here we provide examples of immune profiles and describe a comparison betweenminiaturized assays based on
cytokine secretion or proliferation. We also demonstrate that these assays are convenient for use in testing antigen specificity in
established T-cell lines, in addition to analysis of PBMC. In summary, the applicabilities of miniaturization to save cells and re-
agents and of automation to save time and increase accuracy were demonstrated in this study using different methodological
approaches valuable in the clinical immunology laboratory.
Several conditions lead to defective cellular immunity. In par-ticular, conditioning and immune ablation induced for hemo-
poietic stem cell transplantation (HSCT) in different hematolog-
ical malignant and nonmalignant diseases result in persistent loss
of T cells. Therefore, control of opportunistic infections sustained
by viruses, fungi, and bacteria is lost and several months may
elapse before cellular immune competence reconstitutes (1). Due
to the fact that HSCT is more broadly applied, monitoring of
T-cell responses specific for relevant opportunistic pathogens has
become a relevant issue in the clinical immunology laboratory.
Numerous tests are currently available (2) and efforts are being
made to standardize and validate assays in interlaboratory coop-
erative studies (3). A limitation often encountered with these as-
says is that the number of available peripheral bloodmononuclear
cells (PBMC) needed to test antigens from different pathogens is
insufficient. This is particularly the case with pediatric patients,
due to limited blood volumes, and with lymphopenic patients. In
both cases, miniaturization of assay formats results in a remark-
able advantage, with reagent and cost reductions as additional
benefits. Furthermore, automation that can ormust associatewith
assay format miniaturization may contribute to assay standard-
ization and robustness.
Since different T-cell assays can be used to characterize differ-
ent T-cell functions, such as cytokine synthesis and proliferation
and effector cytolytic activity (2), our goal is to miniaturize most
of these assays to gain more information on the functions and
specificities of responding T cells. We have been engaged in this
effort since we reported on a novel assay performed in 384-well
plates in which antigen-induced cytokine secretion was measured
in the very same culture wells (4). This assay, termed cell enzyme-
linked immunosorbent assay (cell-ELISA), was validated and fur-
ther miniaturized in 1,536-well plates (5, 6). More recently, we
also adapted lymphoproliferation to 384- and 1,536-well plates
(7). Here we describe miniaturization of the enzyme-linked im-
munosorbent spot (ELISPOT) assay and comparative studies be-
tween different types of miniaturized assays.
MATERIALS AND METHODS
Media and reagents. RPMI 1640 (BioWhittaker, Verviers, Belgium) sup-
plemented with 10 mM L-glutamine, 100 g/ml streptomycin, 100 U/ml
penicillin, and 5% autologous heparinized plasma collected after density
gradient separation on lymphocyte separation medium (LSM) (Bio-
Whittaker) was used for cell cultures. Fetal calf serum (FCS) was used at
5% to supplement media for maintenance of antigen-specific T-cell lines.
Recombinant human interleukin 2 (IL-2) (Chiron, Emeryville, CA) was
used at 30 U/ml for expansion of HIV- and cytomegalovirus (CMV)-
specific T-cell lines. Phytohemagglutinin (PHA) (leukoagglutinin; Sigma-
Aldrich, St. Louis,MO)was used at 5g/ml. Tritiated thymidine (specific
activity 6.7 Ci/mmol; Amersham, United Kingdom) was used for pulsing
of PBMC on day 4 for 16 h and for pulsing of T-cell lines on day 2 for 8 to
12 h. Tritiated thymidine was used at a 5-Ci/ml final concentration in
medium.
Antigens. Tetanus toxoid (TT) and purified protein derivative (PPD)
were purchased from Statens Serum Institut, Copenhagen, Denmark.
Cytomegalovirus (CMV) lysate antigen was purchased from Microbix,
Toronto, Canada. Peptides were synthesized by InBios (Naples, Italy) or
by JPT (Berlin,Germany) andused as selected peptide libraries containing
immunodominant CD4 and CD8 peptides (CD4 and CD8 peptide pools
of CMV pp65 antigen) produced as described previously (8, 9, 10). The
HLA-A2 restricted NV9 peptide from CMV pp65 was also used to test
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CD8 responses (10). Final antigen concentrations were 10g/ml for pro-
teins and 1 g/ml for each peptide. Antigens were predispensed in the
culture wells as 10 solutions, corresponding to 5 and 1 l for the 384-
and 1,536-well formats, and stored at20°C for up to 12 months. Using
the different assays, 200, 50, and 10 103 PBMC were seeded in each of
96-, 384-, 1,536-well plates, respectively. For fair comparison between the
different formats, ELISPOT assay and lymphoproliferation results in 96-
and 384-well plates were divided by 20 and by 5 in order to refer to 10
103 PBMC, the cell number seeded in 1,536-well plates.
Materials and instrumentation for miniaturized and automated
processing. Cultures were performed in round-bottom 384- and 1,536-
well plates (number 3671 and number 3937; Corning, Lowell, MA) or in
flat-bottom plates (number 16468 and number 153613; Nunc, Roskilde,
Denmark). The 96-channel Hydra II liquid handler (Matrix Technolo-
gies, Hudson,NH)was used for resuspending [3H]thymidine-pulsed cells
at the end of the culture period and transferring from 384- and 1,536-well
plates to round-bottom 96-well plates that were eventually harvested. The
8-channel dispensers MultiWell (Matrix) and MultiDrop Combi
(ThermoOY,Helsinki, Finland) were used to distribute reagents and cells
in plates.
Donors and PBMC preparation. Healthy donors recruited among
laboratory workers gave their informed consent for this study. The G.
Gaslini Paediatric Institute, where the blood samples were collected, does
not require specific Institutional Review Board approval if an informed
consent for the in vitro study is obtained from the healthy adult donors.
Peripheral blood mononuclear cells (PBMC) were obtained from hepa-
rinized venous blood separated on a conventional density gradient on
LSM. After washing and counting, PBMC were suspended in complete
medium containing 5% autologous heparinized plasma at 1 106/ml.
Cytokine secretion assay (cell-ELISA). The assay was set up and run
as previously described in detail (4). Briefly, plates were coated with the
capture anti-gamma interferon (IFN-) antibody, blocked, and stored at
20°C. Plates were thawed for use and received antigens and cells in
duplicate. After incubation, the plates were frozen again. Before develop-
ment, the thawed plates were washed and developed to reveal captured
IFN-with a second biotinylated antibody, followed by alkaline phospha-
tase-conjugated streptavidin. The cell-ELISA reagents were purchased
from Mabtech, Stockholm, Sweden. After washing, the PNPP phospha-
tase substrate (Sigma, St. Louis, MO) was added and the enzymatic reac-
tion was carried out at room temperature for 30 min. The 384-well plate
reader ELx800 (BioTek, Winooski, VE) and the 1,536-well plate reader
Victor3 (PerkinElmer, Waltham, MA) were used for plate readout. The
plates were read at 405 and the results were plotted against a titration
FIG 1 Representative examples of cell-ELISA. The panels show cell-ELISAs performed on healthy controls. Different individual profiles can be observed using
the assay performed in 384-well plates. Tested antigens included CMV (CMV lysate, pp65 peptide mix, and immunodominant CD4 and CD8 peptides from
pp65), recall antigens (TT andPPD), adenovirus hexon 5 andEBVLMP2peptidemixes, fungal antigens (Candida albicans [Ca],Aspergillus niger [Asp niger], and
Aspergillus fumigatus [Asp fum]). Adeno, adenovirus.
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curve included in each plate to convert optical density (OD) into IFN-
concentrations expressed as ng/ml.
Miniaturized ELISPOT assay. A conventional ELISPOT assay run in
96-well plates (8, 9) was adapted to miniaturized formats. Briefly, PBMC
were cultured and stimulated in 384- and 1,536-well plates with round
bottoms using 50  103 and 10  103 PBMC per well and antigen con-
centrations as described for cell-ELISA. Therefore, also in this case the
PBMC numbers were reduced by 4-fold and 20-fold, respectively, in the
two miniaturized formats, compared to assays run in 96-well plates with
200 103 PBMC. Following a 20-h incubation (activation phase), cells in
thewells were resuspended eithermanuallywith amultichannel pipette or
automatically with a 96-channel liquid handler and transferred to a 96-
well PVDF plate (Millipore, Bedford, MA) precoated with the first anti-
body and containing 200l complete medium (cytokine release and cap-
ture phase). ELISPOT reagents were purchased from Mabtech. Plates
were incubated for an additional 8 h and eventually washed and processed
as for a conventional ELISPOT assay with a second biotinylated antibody,
followed by alkaline phosphate-conjugated streptavidin and ELISPOT
substrate. After development for 1 h at room temperature, spot-forming
units (SFU) were blindly enumerated with a stereomicroscope. Results of
duplicate wells are given as SFU per 10  103 PBMC for all formats for
immediate comparison with ELISPOT assay in 1,536-well plates that use
this cell number for each well.
Miniaturized lymphoproliferation assay. The two-step procedure
for harvesting of pulsed cells in 384- and 1,536-well plates was previously
described in detail (7). Briefly, the plates were pulsed using either a Ham-
ilton syringe to dispense 5 or 1l [3H]thymidine solution at 50Ci/ml in
phosphate-buffered saline (PBS) per well or the automatic dispenser. Af-
ter overnight incubation, the cells in the plates were resuspended and
transferred to round-bottom 96-well plates either manually with a multi-
channel pipette or automatically with the 96-channel liquid handler. At
this stage, the transferred cells were collected from the 96-well plates using
a 96-channel harvester. The dry glass fiber filters were counted with a
Matrix 9600 detector (Canberra Packard, Cambridge,MA) in amixture of
5% argon in nitrogen gas. Results of duplicate wells are shown as counts
per minute (cpm).
Generation, maintenance, and use of HIV-specific and CMV-spe-
cific T-cell lines. HIV-specific CD4 T-cell lines were obtained from two
healthy, seronegative subjects (11–13). Line FM was specific for HIV en-
velope glycoprotein gp120 and recognized the immunodominant peptide
191-205 (PAGFAILKCNNTFNY). Line GLP, specific for HIV reverse
transcriptase p66, recognized the immunodominant peptide 248-262 (K
DSSTVNDIQKLVGK). Briefly, PBMC at 10  106/ml were pulsed with
the relevant peptides at 1g/ml for 4 h at 37°C, diluted 1:5 with medium,
and dispensed in 24-well plates at 2  106/ml at 2 ml per well. IL-2 was
added 4 days later. The cells were split 1:4 when the concentration ex-
ceeded 106/ml. Restimulation cycles were performed every 3 weeks using
3 105 T cells cocultured with 106 autologous, 30-Gy-irradiated PBMC
plus antigen in 2 ml medium. IL-2-expanded T cells were used 3 weeks
after the last stimulation cycle, following a 24-hour resting phase in the
absence of IL-2 to minimize residual proliferative activity. CMV-specific
CD4T-cell lineswere generatedwith a similar protocol, based on repeated
stimulation cycles with antigen-pulsed irradiated autologous PBMC, as
previously reported in detail (9).
Statistics. Results of all assays are shown as mean values of duplicates.
Student’s t test with differences defined as significant at P values of0.01
was used for pairwise comparison of data obtained with different plate
formats.
RESULTS
Four representative examples of specificity profiles obtained by
cell-ELISA are shown in the panels of Fig. 1. Healthy donors ex-
hibited a variety of specific responses, which included recognition
of recall antigens such as TT and PPD; viral antigens from CMV,
Epstein-Barr virus (EBV), and adenovirus; and fungal antigens
such as Candida albicans, Aspergillus niger, and Aspergillus fu-
migatus.
Results from four additional donors were selected as examples
of different specificity profiles obtained by lymphoproliferation in
miniaturized well plates, as shown in Fig. 2. It can be noted that
proliferative responses in 384- and 1,536-well plates yielded
FIG 2 Representative examples of microproliferation assay. The panels showmicroproliferation tested on four healthy subjects using the 96- well (96w) format
and the miniaturized formats in 384- and 1,536-well plates. In all cases cpm are referred to as 10 103 PBMC. Similar reactivity profiles were obtained with the
three formats. Significantly high (P 0.01) cpm values in the smaller format are indicated by an asterisk.
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greater cpm than those in 96-well plates. For easier comparison,
results of 96-well plates were divided by 20 and results of 384-well
plates were divided by 5 to refer to cpm of 10 103 PBMC, as for
those cultured in 1,536-well plates. This trend was occasionally
observed in previous experiments (7), in which proliferation in
384-well plates was compared to proliferation in 1,536-well plates.
It should be noted, though, that a statistically significant differ-
ence was observed in few instances, as indicated in Fig. 2, 3, 4, 5. It
is reasonable to anticipate that differences between formats may
acquire statistical significance by improving the quality of repli-
cates. Refined automation can certainly help attain this goal.
The same four donors were tested in parallel using the two
assays, as shown in Fig. 3. The comparison was performed in 384-
and 1,536-well plates, which were seededwith 50 and 10l PBMC
suspension per well. Even though the results of the two assays are
shown using two different units (IFN- as ng/ml and [3H]thymi-
dine incorporation as cpm), the specificity profiles are similar,
suggesting that both assays detect specific T cells with similar effi-
ciency. In fact, negligible responses to TT were detected in two
donors, while responses to the other tested antigens were consis-
tently positive with both assays. Results for cell-ELISA in the two
formats are similar, since IFN- concentrations are expected not
to differ in the culture supernatants. In contrast, in the case of
lymphoproliferation, total [3H]thymidine incorporation as cpm
depends on the number of harvested PBMC. For an easier com-
parison between the two formats, cpm for 384-well plates were
divided by 5 and thus referred to as 10 103 PBMC, as seeded in
the 1,536-well plates. Sensitivity thresholds (detection of low fre-
quencies of specific T cells) were not analyzed using PBMC but,
rather, using established T-cell lines, as described later.
Four healthy donors responsive to CMVwere testedwith recall
antigens and different CMV antigens by ELISPOT assay per-
formed in standard 96-well plates and in miniaturized plates. Fig-
ure 4 shows the SFU counts referred to as 10  103 PBMC for
easier comparison. Overlapping response profiles were obtained
in all subjects responding to different antigenic challenges. It
should be noted that higher SFU counts were consistently ob-
served in the smaller formats than SFU in 96-well plates, with
significant differences between 1,536- and 384-well plates in a few
cases, as indicated in the Fig. 4 legend.
We have previously described a remarkable assay correlation
using cell-ELISA in 384-well plates and ELISPOT assay in 96-well
plates (G. Li Pira, F. Ivaldi, N. Starc, F. Landi, S. Rutella, F. Loca-
telli, N. Sacchi, G. Tripodi, F. Manca, submitted for publication).
Here we provide amore extensive comparison of the two assays in
which cultures were performed in the miniaturized formats of
384- and 1,536-well plates (Fig. 5). PBMC were stimulated with
recall and CMV antigens to include proteins and peptides. Two
CMV responders were tested. The SFU counts referred to as 10
103 PBMC in the two formats are shown in the left panels. Similar
FIG 3 Comparison of cell-ELISA and microproliferation. Four healthy donors were tested with the two assays in miniaturized formats (384- well plates, open
bars, and 1,536-well plates, gray bars). Cell-ELISA results are comparable in the two formats since they refer to IFN- concentrations in culture conditions in
which PBMC are at the same density. On the contrary, microproliferation results shown for 384-well plates were divided by 5 to show proliferation of 10 103
PBMC for comparison with results obtained in 1,536-well plates. This correction showed that the two formats provide similar results, with a consistent, but not
significant, trend for higher efficiency of the 1,536-well format than of the 384-well format.
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profiles were obtained, with a higher efficiency for the smaller
formats consistently confirmed, even though a significant differ-
encewas not observed. The ELISPOT assay profileswere similar to
those of the cell-ELISA profiles depicted in the right panels.
Established T-cell lines were available in the laboratory from
different donors and with different specificities. From this panel,
we chose two T-cell lines specific for two HIV antigens that had
been generated from seronegative, nonimmune subjects. This
proved particularly convenient, as the frequency ofHIV-specific T
cells in PBMC from these donors, used as a source of antigen-
presenting cells for T-cell stimulation, was below the detection
threshold. Figure 6 shows IFN- production and proliferative re-
sponses of T-cell lines that weremeasured in parallel assays in 384-
and 1,536-well plates. In the first case, each well contained 50 
103 irradiated autologous PBMC plus 5,000, 500, 50, 5, and 0
specific T cells from the established lines in a 50-l volume. In the
second case, each well contained one-fifth of the same cellular
reagents, corresponding to 10 103 irradiated autologous PBMC
plus 1,000, 100, 10, 1, and 0 T cells from the established lines in 10
l. The results of the two parallel assays were in agreement, inde-
pendently of the format. With respect to sensitivity, it can be seen
that in most cases using cell-ELISA or lymphoproliferation, be-
tween 5 and 10 specific T cells can be detected using the 384- and
the 1,536-well plates. These figures correspond to actual frequen-
cies of specific T cells of 5/50,000 (0.01%) and 10/10,000 (0.1),
that are in the lower range of expected frequencies of antigen-
specific T cells among PBMC.
Experiments using CMV-specific CD4 T-cell lines are shown
in Fig. 7. In this case, the lines generatedwith thewhole-CMVviral
lysate were responsive to a pool of overlapping peptides corre-
sponding to the immunodominant pp65 protein. Therefore, the
assays were run using the pp65 peptide mix. Similar results were
obtained using HIV-specific and CMV-specific T-cell lines, with
similar detection thresholds (0.01% to 0.1%) for the lowest cell
concentrations.
DISCUSSION
The reasons for running functional T-cell-specificity assays in
miniaturized and automated formats have already been outlined
in the introduction and discussed in depth in previous papers
(2–4). The experiments we reported here address additional
points and lead to several conclusions.
First of all, informative specificity profiles were obtained using
different assays in miniaturized (384-well plates) and ultraminia-
turized (1,536-well plates) formats. This confirms that very few
cells can be used, thus making it possible to test a single antigen
with 50  103 or 10  103 PBMC with the two formats, respec-
tively, instead of 200  103 to 400  103 PBMC using conven-
tional 96-well plates.
Second, there was a good agreement between cell-ELISA and
lymphoproliferation both in 384- and 1,536-well plates. This ob-
servation has already been reported with 384-well plates (7). The
extension to the 1,536-well format is encouraging, since this
should be the ultimate plate format to save cells and reagents, if
some manipulation problems are worked out. These plates, in
fact, require automated processing, as manual handling can be
inaccurate and confusing, resulting in antigen mix up or poor
replicates. Automated liquid dispensers, washers, and readers that
FIG 4 ELISPOT assay in miniaturized format. Healthy donors were challenged with protein antigens (TT, PPD, CMV lysate, pp65) and with peptide antigens
(pp65 peptide mix, CMV CD4 T-helper peptide pool, and CMVCD8 CTL [cytotoxic T lymphocyte] peptide pool). SFU were referred to as 10 103 PBMC for
the three 96-, 384-, and 1,536-well formats. A consistent increase in SFU counts is evident with the smaller formats, indicating an increased efficiency of the
miniaturized cultures. Significantly high (P 0.01) SFU counts in the smaller formats are indicated by asterisks.
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can handle 384- and 1,536-well plates are not often present in the
standard clinical immunology laboratory. Nevertheless, since
their use can be extended to otherminiaturized cellular immunol-
ogy assays, as shown here, in addition to immunochemical and
molecular biology assays, their availability should be considered in
future perspectives.
It should be noted here that the assays remarkably differ in
duration (1 day for cell-ELISA or ELISPOT assay, 5 days for lym-
phoproliferation). Therefore, a preliminary profile can be ob-
tained by the next day, but confirmation that specific T cells carry
a proliferative potential is available on day 5. The similarities be-
tween the two assays in the healthy donors we tested suggest that
the lymphoproliferation assay may be dispensable, with antigen-
driven production of IFN- reliably anticipating the proliferative
response. Unfortunately, we do not know yet if this conclusion
can be extended to patients with compromised cellular immunity.
Particularly in patients receiving immunosuppressive drugs, cyto-
kine secretion does not grant clonal expansion potential, and a
functionally relevant discrepancymay exist between effector func-
tion and proliferative potential of memory T cells. Therefore, spe-
cific studies aimed at solving these questions need to be under-
taken.
Third, the sensitivity issuewas considered in light of assaymin-
iaturization. In fact, volume reduction is simply a technicality,
which can be addressed using accurate instrumentation inmolec-
ular assays that measure antibodies, other analytes, or nucleic ac-
ids. On the contrary, assay volume reduction in cellular assays
must take into account the frequency of specific cells, which may
be under limiting dilution conditions if reaction volumes are re-
duced beyond a given threshold. In fact, two parameters should be
kept inmind. One is assay sensitivity, i.e., the number of specific T
cells responding to a given antigenic stimulus that the can test
reveal as a positive signal; the other one is the frequency of specific
T cells among PBMC. In previous studies (4, 6), we have ascer-
tained that cell-ELISA can detect IFN- secreted by as few as 2 to 5
specific T cells. Using limiting dilutions, we also showed thatmin-
iaturized proliferation can detect similar numbers of specific T
cells (7). Here, we ran a comparative sensitivity assessment on the
sameT-cell samples, using establishedT-cell lines. This permits an
accurate knowledge of the number of input-specific T cells per
well, the same information being hard to gain using PBMC. As
illustrated in the Results section, assuming a reasonable frequency
of 0.1% T cells specific for a pathogen like CMV, one specific cell
out of 1,000 PBMC can be detected. If the assay threshold is 5
specific T cells, at least 5,000 PBMC need to be cultured to detect
a positive signal. To stay on the safe side, 10,000 PBMC should be
seeded in the 1,536-well plate. This figure cannot be further re-
duced, unless higher frequencies of specific T cells are expected. A
more detailed discussion on the issue of precursor frequency and
liminal detection has been previously presented (14).
Fourth, a comment should be made regarding the higher effi-
ciency of cultures performed in microplates than in standard 96-
well plates. In fact we observed a consistent trend for higher re-
sponses in the smaller formats (384- versus 96- and 1,536- versus
384-well plates), as if responding T cells “appreciated” the smaller
culture wells. A possible explanation is that, even if PBMC con-
centrations were identical and thus cell densities at the bottom of
flat wells would have been the same, the smaller radius in the
smaller round-bottom wells increased cell density. This likely re-
sulted in a microenvironment in which contacts between specific
T cells and antigen-presenting cells (APC) were facilitated. This
condition, in fact, is closer to the three-dimensional (3D) struc-
ture of a lymphoid organ than the 2D condition of a flat-bottom
well. This hypothesis demands more targeted experiments, but, if
FIG5 Comparison ofminiaturized ELISPOT assay and cell-ELISA. Two healthy donors were testedwith a restricted antigen panel to include proteins (TT, PPD,
CMV lysate) and peptides (CMV pp65 peptide mix). The ELISPOT assay SFU counts in the left panels are referred to as 10 103 PBMC for the two 384- and
1,536-well formats in order tomake results of the two formats comparable. Significantly high (P 0.01) SFU counts in the smaller format indicated by an asterisk
were seen in one case only, but a consistent trend for higher efficiency of the 1,536-well format was evident. Cell-ELISA results, given as ng/ml IFN-
concentration, were not corrected for plate format, as described in legend to Fig. 3.
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proven, it may provide additional support to the fact that the
principle “the smaller the better” also applies to T-cell assays as
long as miniaturization does not dilute out specific T cells to un-
detectable thresholds. It is also likely that PBMC resuspension
allows a more efficient collection of all PBMC in the proliferation
assay. Likewise, thorough dispersion of PBMC after collection of
miniaturized ELISPOT assay plates before transferring to 96-well
plates for cytokine capture and immunoenzymatic development
may disrupt clusters of specific T cells surrounding a single APC
(15) and thus reveal individual spot-forming cells rather than
FIG 6 Titration of HIV-specific T-cell lines spiked in autologous PBMC. The left panels indicate cell-ELISA results and the right panels indicate lymphopro-
liferation results. Upper graphs refer to an HIV gp120-specific T-cell line generated from donor FM47, while lower graphs refer to an HIV reverse transcriptase-
p66-specific T-cell line generated from donor GLP61. Graded numbers of specific T cells were titrated in autologous irradiated PBMC as a source of antigen-
presenting cells. Titrations were performed in 384- and 1,536-well plates. The horizontal axes indicate the percentage of T cells versus total PBMC, and the
absolute numbers of specific T cells per well at the different dilutions for the two formats.
FIG 7 Titration of CMV-specific T-cell lines spiked in autologous PBMC. The left panels indicate cell-ELISA results and the right panels indicate lymphopro-
liferation results. Graded numbers of specific T cells obtained from CMV-specific T-cell lines generated from donors FM47 and GLP61 were titrated in
autologous irradiated PBMC as a source of antigen-presenting cells. Titrations were performed in 384- and 1,536-well plates. The horizontal axes indicate the
percentage of T cells versus total PBMC, and the absolute numbers of specific T cells per well at the different dilutions for the two formats.
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spot-forming units. This case, as an artifact, may underestimate
the actual frequency of specific T cells in standard ELISPOT assays
and thus this may be an additional advantage for the two-step
procedure in 384- and 1,536-well plates.
In conclusion, miniaturization and automation of assays that
monitor antigen-specific T-cell immunity is feasible and can be
further improved in order to save cells and reagents, to increase
assay reliability and robustness, and to broaden clinical applica-
tions. These improvements result in remarkable benefits for the
monitoring of specific cellular immunity (16–18) in cancer im-
munotherapy, immune deficiencies, and immune reconstitution
associated with various conditions. In the more specific field of
adoptive immune reconstitution (19), these assays may help to
identify patients requiring adoptive immunotherapy before severe
infections break out, select the most appropriate donor for T-cell
immune reconstitution, and define successful immune restora-
tion.
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